EPIVIR-HBV (LAMIVUDINE) — FDA Approval NDA021003 (GLAXOSMITHKLINE)
EPIVIR-HBV (LAMIVUDINE) — FDA Approval NDA021003 (GLAXOSMITHKLINE) is one of 9,000 drug approvals in the DrugApprovals dataset. Key details — Brand name: EPIVIR-HBV; Active ingredients: LAMIVUDINE; Application number: NDA021003.
| Brand name | EPIVIR-HBV |
|---|---|
| Active ingredients | LAMIVUDINE |
| Application number | NDA021003 |
| Sponsor | GLAXOSMITHKLINE |
| Dosage form | TABLET |
| Route | ORAL |
| Marketing status | Discontinued |
| Products in application | 1 |
| First approval date | 19981208 |
| Source | openFDA Drugs@FDA |
$1499/mo
Try DrugApprovals →